Posts

Showing posts with the label Cancer

miRNA-Based Therapies: Revolutionizing Cancer Treatment Strategies

Image
Micro RNAs (miRNAs) are small non-coding RNA molecules that play a pivotal role in regulating gene expression post-transcriptionally. Since their discovery in 1993, miRNAs have been identified as key players in various cellular processes, including development, proliferation, differentiation, apoptosis, and stress response [1] . In recent years, miRNAs have gained significant attention in the field of cancer research due to their involvement in tumorigenesis, metastasis, and treatment resistance. This article delves into the intricate relationship between miRNAs and cancer, highlighting their potential as therapeutic targets and exploring the challenges and opportunities of utilizing miRNA-based therapies. miRNAs function by binding to complementary sequences within the 3' untranslated regions (UTRs) of target mRNAs, leading to mRNA degradation or translational repression. This intricate interaction allows miRNAs to fine-tune the expression of numerous genes, ultimately influe...

CANCER BREAKTHROUGH: Programmable Self-Regulated Nano Transporters

Image
Cancer might be a disease from the past couple of centuries, but only the technology to cure it has only been starting to develop these days. With such innovations, many cancers are highly probable of being cured, if diagnosed early, meaning higher chances for cancer patients to live longer.   The cancer epidemic is one of the crucial global health issues, at present, accounting for around 10 million deaths every year. In 2022, studies estimated about 1.9 million incidents and 609,360 deaths will be reported from malignancy in the United States, alone [1] . Luckily, preventative measures are accessible. Around 30-50% of all cancer cases are currently preventable through a series of procedures to avoid or reduce exposure to risk factors, such as smoking cessation programs for smokers [2] . The number of cancer patients who survived through traditional clinical therapies was just about 25%, which has now improved to nearly 50% [3] . As a result, targeted therapy is now a cur...